SCHEMBL6844797

SCHEMBL6844797

CC(C)(C)OC(=O)N1CCN(c2cccc(NC(=O)c3cccc(CCc4cnc5[nH]cnc5c4)c3)c2C(F)(F)F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.39
BACE1 P56817 2/20 0.39
TSHR P16473 3/20 0.39
HSD17B10 Q99714 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
ATM Q13315 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPK1 P28482 1/20 0.37
F2 P00734 1/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPK8 P45983 1/20 0.37
MAP3K20 Q9NYL2 1/20 0.36
KIT P10721 1/20 0.36
FLT3 P36888 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846841 0.91 HTT (0.37) METBACE1TSHRHSD17B10RXFP1
SCHEMBL6844794 0.89 MAP3K20 (0.39) METBACE1ATMMEN1KMT2A
SCHEMBL6846828 0.86 LCK (0.44) BACE1TSHRHSD17B10RXFP1F2
SCHEMBL6846514 0.85 TSHR (0.42) METBACE1TSHRHSD17B10RXFP1
SCHEMBL6841382 0.84 WNT3A (0.41) METBACE1TSHRHSD17B10RXFP1
SCHEMBL6848356 0.84 ALDH1A1 (0.43) METBACE1TSHRHSD17B10RXFP1
SCHEMBL6846784 0.81 TEK (0.39) BACE1RXFP1ATMF2POLB
SCHEMBL6846837 0.80 MAP3K20 (0.36) METATMMEN1KMT2AMAPK1
SCHEMBL6846441 0.78 TSHR (0.47) BACE1TSHRHSD17B10RXFP1ALDH1A1
SCHEMBL6846825 0.74 ABL1 (0.42) KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA MET 692/4885BACE1 2355/4885TSHR 2259/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA MET 692/4885BACE1 2355/4885TSHR 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.